Stem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT – The Arctic University of Norway, Tromso, Norway
Ruba Almaghrabi
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Laboratory Medicine (hematology), Faculty of Applied Medical Sciences. Albaha University, Kingdom of Saudi Arabia, Al Bahah, Saudi Arabia
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom; Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom
Ashok Kumar Rout
Institute of Chemistry and Metabolomics, University of Lübeck, Lübeck, Germany
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom
Elena González
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom
Yara Alyahyawi
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom; Department of Medical Laboratories Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia
Alan Cunningham
Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Ayşegül Erdem
Department of Experimental Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Frank Schnütgen
Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany; Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt, Germany; German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, and German Cancer Research Center (DKFZ), Heidelberg, Germany
Manoj Raghavan
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom; Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Birmingham, United Kingdom
Sandeep Potluri
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom; Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Birmingham, United Kingdom
Jean-Baptiste Cazier
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom; Centre for Computational Biology, University of Birmingham, Birmingham, United Kingdom
Stem Cells, Ageing and Cancer Research Group, Department of Medical Biology, Faculty of Health Sciences, UiT – The Arctic University of Norway, Tromso, Norway
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom; Institute of Chemistry and Metabolomics, University of Lübeck, Lübeck, Germany
Acute myeloid leukaemia (AML) cells interact and modulate components of their surrounding microenvironment into their own benefit. Stromal cells have been shown to support AML survival and progression through various mechanisms. Nonetheless, whether AML cells could establish beneficial metabolic interactions with stromal cells is underexplored. By using a combination of human AML cell lines and AML patient samples together with mouse stromal cells and a MLL-AF9 mouse model, here we identify a novel metabolic crosstalk between AML and stromal cells where AML cells prompt stromal cells to secrete acetate for their own consumption to feed the tricarboxylic acid cycle (TCA) and lipid biosynthesis. By performing transcriptome analysis and tracer-based metabolic NMR analysis, we observe that stromal cells present a higher rate of glycolysis when co-cultured with AML cells. We also find that acetate in stromal cells is derived from pyruvate via chemical conversion under the influence of reactive oxygen species (ROS) following ROS transfer from AML to stromal cells via gap junctions. Overall, we present a unique metabolic communication between AML and stromal cells and propose two different molecular targets, ACSS2 and gap junctions, that could potentially be exploited for adjuvant therapy.